FGFR4 overexpression
|
CRC
|
FGFR4 overexpression
|
CRC
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
FGFR4 overexpression
|
HCC
|
FGFR4 overexpression
|
HCC
|
lenvatinib Sensitive: C4 – Case Studies
|
lenvatinib Sensitive: C4 – Case Studies
|
FGFR4 overexpression
|
Liposarcoma
|
FGFR4 overexpression
|
Liposarcoma
|
erdafitinib Resistant: D – Preclinical
|
erdafitinib Resistant: D – Preclinical
|
FGFR4 overexpression
|
Breast Cancer
|
FGFR4 overexpression
|
Breast Cancer
|
FGFR inhibitor Sensitive: D – Preclinical
|
FGFR inhibitor Sensitive: D – Preclinical
|